All Issues
Drug repurposing for Breast Cancer: Preliminary medicinal chemistry investigations and future perspectives
Author : Prashant S. Kharkar *a,b, Chetan P. Shah b and Niteshkumar U. Sahu b
DOWNLOAD PDF
ABSTRACT
Triple-negative breast cancer (TNBC) is one of the leading causes of mortality in women. Despite the availability of varied treatment modalities, including chemotherapeutic and immunotherapeutic drugs, TNBC remains a major health concern worldwide. In the present study, we investigated the drug repurposing for TNBC with the hope to identify safer and efficacious drugs for its treatment. Of the 70 drugs tested against highly metastatic MDA-MB-231 cell line in MTT assay, a total of 11 drugs demonstrated potent cytotoxicity. Further in vitro and in vivo (animal efficacy) biological investigations are needed to prove the anti-TNBC potential of the identified hits – Domperidone, Candesartan cilexetil, Felodipine, Atorvastatin calcium, Sertraline HCl, Nisoldipine, Lopinavir, Clotrimazole, Desloratadine, Carvedilol phosphate and amlodipine besylate.
KEYWORD
Breast Cancer, TNBC, drug repurposing, MDA-MB-231, MTT